Researchers are testing changes intended to improve the care and management of patients who present to the ED with behavioral health concerns. Providing trauma-informed care to these patients is critical to any improvement effort. Further, EDs should find ways to provide early treatment to these patients rather than just focusing on ways to transfer them elsewhere.
The 2019-2020 flu season is already among us, and it is imperative that those healthcare practitioners on the frontline, particularly in our nation’s emergency departments, have current knowledge of prevention and treatment strategies.
In an open-label, non-randomized clinical trial using a second course of intravenous immunoglobulin (IVIg) to treat patients with Guillain-Barré syndrome, no benefit was observed. A single course of 2 g/kg of IVIg should be administered. No additional treatment is helpful.
The PRIMA study is a randomized, double-blind, multi-institutional, international phase 3 trial testing the PARP inhibitor niraparib against placebo after first-line standard treatment with platinum-based chemotherapy for newly diagnosed ovarian cancer.
Simply reducing the number of opioid prescriptions is not enough, the report authors wrote. Hospitals must be much more proactive in identifying patients with opioid use disorder and initiating treatment wherever those patients are encountered within the treatment process.
This article will review psychosis within myriad differentials and discuss the potential workup and medication options for the management of these patients to help equip the emergency provider with the tools necessary to care for this unique population.